RemedyBio utilizes ultra high throughput single-cell analysis technology to map immune cell functions directly from patient biology, enhancing the development of immunotherapies for complex diseases. This approach addresses the need for more effective therapeutic and diagnostic solutions in immuno-oncology, autoimmune diseases, and infectious diseases.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective immunotherapies for complex diseases is hindered by the difficulty of comprehensively mapping immune cell functions directly from patient biology. Current methods lack the throughput and resolution needed to fully understand the intricate interactions within the immune system. This limitation slows down the identification of promising therapeutic targets and the development of targeted diagnostic solutions.
Solution
RemedyBio is developing a platform that utilizes ultra-high-throughput single-cell analysis to deeply profile immune cell functions. By directly analyzing patient samples at the single-cell level, the platform aims to provide a more detailed understanding of immune responses in complex diseases. This approach enables the identification of novel therapeutic targets and the development of more effective immunotherapies. The platform's high-throughput capabilities allow for the analysis of a large number of cells, providing a comprehensive view of the immune landscape.
Target Audience
The primary target audience includes biopharmaceutical companies and research institutions involved in developing immunotherapies for immuno-oncology, autoimmune diseases, and infectious diseases.
Features
- Ultra-high-throughput single-cell analysis for deep immune profiling
- Direct mapping of immune cell functions from patient samples
- Identification of novel therapeutic targets for immunotherapy development
- High-resolution analysis of immune cell interactions